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ABSTRACT 
 
Current needle-free injection technology is based on actuation via compressed springs or gas.  
These devices are not easy to modify for different depths of injections.  This thesis describes the 
design and verification of a handheld needle-free device which is capable of various injection 
depths via electrical control of a Lorentz-force voice coil actuator.  A benchtop proof-of-concept 
device was created to prove the concept of needle-free injection using a voice coil.  After the 
successful testing of the proof-of-concept device, a handheld prototype was designed, 
manufactured, and tested.  The controllability of injections was tested on excised sheep tissue in-
vitro.  The handheld device was also tested in-vivo on sheep midside and was shown to give 
comparable injections to a needle for delivery of the drug collagenase.  The controllable needle-
free injection principles described in this thesis could be used in human or veterinary 
applications. 
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 1 Introduction 
 
Drug delivery using needles has been standard practice since the mid-nineteenth century [12].  
Needles have been used to inject a variety of drugs into the body, particularly those that need to 
be delivered locally like anesthetics or those that would be degraded or destroyed if taken orally.  
Needle injections of vaccines have been successful at eradicating diseases such as Rubella and 
Polio in the USA.   
 
However, some people suffer from a phobia of needles (Trypanophobia), needle sticks are often 
painful, and cross-contamination of patients and healthcare providers from accidental needle 
stick injuries make needle injections dangerous.  In fact, the majority of percutaneous injuries in 
health care workers are due to needles (as shown in Figure 1).   
 
 
 
 
Figure 1: Devices involved in percutaneous injuries, (n=13,731 healthcare workers).  Figure from 
the Centers for Disease Control Sharps Safety Workbook [1]. 
 
 
Therefore, a method of injection that does not involve needles or the pain and dangers associated 
with them could lead to improved healthcare across the planet.   
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2 Background and Motivation 
2.1 Needle-Free Injection 
Due to the problems that needles pose, researchers have studied other ways of drug delivery and 
determined that needle-free injection (NFI) was a viable alternative.   
2.1.1 Historical Context 
Needle-free injection was first described in the literature in 1947 as a drug delivery method that 
would make traditional needle injections obsolete [10].  Needle-free injection is performed by 
ejecting a high-pressure fluid through a small diameter nozzle into tissue.  It was used beginning 
in the 1950s by the military for inoculations but its use was limited when researchers proved that 
blood-borne diseases such as Hepatitis B could be spread by the NFI devices from patient to 
patient [7]. 
2.1.2 Current Technology 
Current needle-free technology used in the human market centers around single-use devices (in 
which the portion that is in contact with the skin is disposed after each injection).  The injectors 
on the market are powered by compressed springs or gas [19] [18] [15] [20] [14] [17] [16] [21] 
[30] [24].  A common use for NFI today is insulin injection for diabetic patients.  This market 
responds well to NFI due to the frequency of injections.  The pain of frequent needle-sticks often 
causes a psychological aversion to needles among diabetics.  NFI is good for these patients due 
to the lack of a needle.  It is also useful for young patients, with several NFI devices being 
marketed especially for children.  BioJect [6] developed the cool.click for delivering human 
growth hormone to pediatric patients (Figure 2a) and markets an optional set of Elephant EarsTM 
for use on their Biojector NFI device (Figure 2b).   
 
 
.
 
Figure 2: (a) The cool.click system from Bioject for in
pediatric patients and (b) optional Elephant EarsTM for
from www.bioject.com). 
2.2 Animal Husbandry 
Field veterinary medicine suffers from many of th
human medicine.  It is often desirable to perform m
may occur in a farm setting where using and disposin
Therefore, NFI would be an excellent solution for an
because of the frequently remote locations involved
device that was capable of many different kinds of in
 7ba.
 
jecting human growth hormone into 
 use with the Biojector 2000. (Figures taken 
e same dangers associated with needles as 
any injections rapidly, and these injections 
g of needles is dangerous and inconvenient.  
imal husbandry applications.  Additionally, 
, it would be especially beneficial to have a 
jections with minimal changeover time.   
3 Controllable NFI Project Goals 
 
After reviewing current needle-free injection technology and applications, it became apparent 
that a controllable device capable of different depths of injections would be useful in both human 
and animal applications.  With input from a sponsoring pharmaceutical company, Norwood 
Abbey Inc., of Victoria, Australia, we decided to design, build, and test an NFI device for the 
veterinary market.  This device has the following functional requirements: 
 
• Able to inject lambs 
• Handheld  
• Able to quickly change injection parameters 
• Operates on battery power 
• Automatically reloads with fluid for sequential injections 
• Delivers at least 100 µL per injection 
• Produces fluid injection pressures of at least 60 MPa 
• Runs for at least 500 cycles without refilling with fluid or recharging the battery 
 
In order to design a device with these constraints, we conducted an analysis of current needle-
free injection theory. 
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4 Needle-Free Injection Theory: Mechanical Models 
 
When needle-free injection was first described by Hingson and Hughes [10], they were not 
concerned with the mechanics of jet injection but instead focused on the results of successful 
injections.  Their analysis of injection parameters was purely empirical, based on results of 
injections into humans and cadavers.  They only specify “the fact that extremely fine high 
pressure jets are capable of piercing the human skin,” [10] and dedicate the rest of their paper to 
results of patient testing.  Subsequent research in this area has focused on understanding the 
effects of needle-free injection parameters through modeling injections into synthetic skins. 
4.1 Polyacrylamide Testing 
Polyacrylamide gels is often used to simulate tissue.  Most recently, Schramm-Baxter and 
Mitragotri used polyacrylamide gels to investigate the properties of a commercially-available 
NFI device [25].  They hypothesized that needle-free injection occurs in two phases: creation of 
a central hole, and the spreading of the fluid as if it originated from a point source at the bottom 
of the hole. (Figure 3). 
 
 
 
 
Figure 3: “The evolution of jet penetration during the injection into 20% acrylamide gel (orifice 
diameter 152 µm, velocity of 180 m/s, volume of 0.076 ml).  The presence of an introductory 
channel and fluid dispersion is already evident by 11.1 ms.  The jet enters the gel at the 
black/white interface.”  Figure and text from [25]. 
 
 
Use of polyacrylamide gel as a tissue model is limited because of its homogeneity; the 
polyacrylamide gel does not adequately represent the different layers of tissue near the surface of 
the skin.  Also, the gel has a tendency to fracture along planes or crack (as visible in Figure 4 
from [25]), which is not representative of tissue behavior.   
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Figure 4: “A polyacrylamide gel containing 20% acrylamide was jet injected from 1mm above the top of the gel at 
170 m/s with 0.076 ml of fluid of which the majority penetrated into the gel (152 mm diameter nozzle). (a) The 
general shape of the jet penetration into the gel has an introductory channel followed by a circular dispersion. A hole 
is present in the gel within the introductory channel. (b) Side view of the same gel shown in part (a).  The figure 
shows dispersion of the jet in the gel is two dimensional.” Figure and text from [25]. 
 
4.2 Model Of NFI Parameters For Injections Into Tissue 
The research conducted by Schramm-Baxter and Mitragotri also described injections into tissue 
using needle-free injection.  They proposed a model that postulates that the depth of the injection 
is a function of the power of the fluid jet when it exits the device nozzle [25] [27].  Using 
conservation of energy of the fluid at the nozzle and assuming a flat velocity profile in the fluid, 
the power at the nozzle is 
 
2
2
1
nn umP &= ,           (1) 
 
where Pn is the jet power at the nozzle,m is the mass flow rate through the nozzle, and  is the 
fluid velocity at the nozzle.  The mass flow rate is defined as 
&
nu
 
      nn uAm ρ=& ,           (2) 
 
where ρ  is the density of the fluid and the area of the nozzle is .  The area of the nozzle in 
terms of the diameter is 
nA
 
      
4
2
n
n
DA π= .           (3) 
 
Therefore, the jet power at the nozzle in terms of the fluid density, nozzle diameter, and fluid 
velocity at the nozzle is 
 
      32
8 nnn
uDP ρπ= .          (4) 
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However, it is extremely difficult to measure the fluid velocity at the nozzle.  Therefore, we 
conducted experiments to find a model that could approximate the fluid velocity from other 
parameters that are easier to measure.  In our model, we determined the velocity from the 
pressure of the fluid in the cylinder using the Bernoulli Equation, giving 
 
      pun ρ2= ,           (5) 
 
where p is the pressure of the fluid that is being injected.  Combining Equations 4 and 5, the jet 
power in terms of the fluid density, nozzle diameter, and pressure is 
 
2/322/5
8
pDP nn ρπ= .         (6) 
 
The Bernoulli Equation involves several simplifications, including steady inviscid flow, constant 
fluid density, and no heat or work transfer through the fluid.  At first, it appears that the NFI fluid 
flow may not meet these criteria.  Experiments were performed to see if the Bernoulli Equation 
could predict reasonable fluid velocities.  The pressure in the fluid during the injection was 
measured every 100 µs.  For each pressure data point, the mass flow rate was calculated by 
combining Equations 2 and 5: 
 
      pAm n 2
2/3ρ=& .          (7) 
 
Integrating the calculated mass flow during the time of the injection yielded a theoretical volume 
of fluid ejected which was then compared to the measured volume of fluid ejected through the 
nozzle.  (See Matlab [21] program written for calculating jet power and integrating volume of 
fluid ejected in Appendix B.)  The Bernoulli estimate was compared with estimates from models 
that took into account possible viscous losses, turbulence, or entry regions.  However, the 
Bernoulli model best predicted the measured volume ejected by the device, and the model 
described by Equation 6 was used as the working model during the duration of the project.   
 
An important improvement in our model over the Schramm-Baxter model of jet injection was 
our calculation of the jet power at every sampled data-point.  Schramm-Baxter only used the 
average jet pressure over the entire injection to calculate jet power [25] [27].  However, due to 
the controllability of this NFI device, we needed to measure and understand the jet power 
throughout the course of the injection.   
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5 Benchtop Proof of Concept 
 
To demonstrate the feasibility of an electrically-controllable NFI device, a benchtop proof-of-
concept device was developed first.  A voice coil was selected as the controllable actuator so that 
the pressure of the fluid could be varied during the injection, thus varying the jet power during 
the injection.  A functional diagram of the device is shown below (Figure 5). 
 
 
Voice Coil Nozzle
Position Pressure
Piston Fluid in DrugCylinder
Programmed
Control Logic
Power
Amplifier
Voltage &
Current
Drug
Reservoir  
 
Figure 5: Functional Diagram of the controllable needle-free injector.  The path of action is shown 
with black arrows.  Sensor feedback is shown by red arrows.   
 
5.1 Device Design 
The benchtop device was oriented vertically, so that the sample could be simply placed 
underneath.  The components were aligned axially and mounted using Macrobench 
components [21].  Figure 6 shows a model of the device and the actual implementation. 
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Figure 6: Benchtop proof-of-concept controllable needle-free injection device.  The CAD drawing 
is on the left and the actual device is on the right.     
5.1.1 Voice Coil 
A commercially-available voice coil (BEI Kimco Magnetics [5] model LA25-42-000A) was 
selected for use in the device.  The coil is rated for 266 N of continuous stall force, with a DC 
resistance of 2.4 Ω and a force constant of 21 N/A.  The total stroke is 25.4 mm.  The force 
output as a function of position was determined by labmate Nathan Ball, as shown in Figure 7. 
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Figure 7: Plot of force available from voice coil as a function of its position at 10 Amperes.  
Experiment and analysis performed by Nathan Ball. 
 
The magnetic properties of the coil were also modeled in ANSYS 8.1 [3] by Dr. Andrew 
Taberner (Figure 8).  This modeling was used to confirm that the selected voice coil was capable 
of the required force.  Also, an understanding of the magnetic field in the voice coil would be 
important to Dr. Taberner’s ongoing project to design and build an optimum voice coil for this 
application.   
 
 
Coil Center
Outside
 
 
Figure 8: ANSYS 8.1 model of the magnetic field in the BEI Kimco model LA25-42-000A voice 
coil.  Note the non-uniformity of the field, which corresponds to the varying force over 
displacement shown in Figure 7. (Modeling and figure courtesy of Dr. Andrew Taberner).   
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5.1.2 Piston Assembly 
Connecting the voice coil to the rest of the system was a central shaft, also called the piston 
assembly.  A 6.35 mm shaft was attached to the coil of the voice coil actuator and extended up to 
the position sensor and down to a coupler that linked to a force sensor.  Below the force sensor 
there was a 3 mm shaft (“the piston”) that fit tightly into the drug cylinder.     
5.1.3 Drug Cylinder and Nozzle 
The drug cylinder was designed to hold the fluid to be injected, interface with the nozzle, piston, 
and pressure sensor, and allow for filling and refilling with minimal trapped air.  Therefore, the 
drug cylinder (Figure 9) was a complicated element designed and machined primarily by Brian 
Hemond, a graduate student in the BioInstrumentation Laboratory.    
 
The 3 mm piston entered the drug cylinder at the central bore (at the top of the figure).  The 
central bore was filled with fluid by the refill port on the right side.  A ball check valve allowed 
fluid to enter the system via the refill port but prevented the fluid from back-flowing when the 
device was fired.  On the left side of the drug cylinder, there were bores for a pressure sensor 
(described in Section 5.1.4) and a bleed port; the bleed port was opened during the initial filling 
of the system to allow trapped air to escape.  At the bottom of the drug cylinder was the nozzle.  
The nozzle was a separate component that had a central bore aligned with the drug cylinder 
central bore and an orifice at its end.  The orifice was 100 µm in diameter and created by 
microdrilling the end of the nozzle.   
 
Bleed Port
Pressure 
Sensor Bore
Nozzle
Central Bore
Refill Port
Check Valve
Bore
 
Figure 9: Cross-section of benchtop prototype drug cylinder, designed by Brian Hemond. 
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5.1.4 Sensors 
The benchtop proof-of-concept device was equipped with 3 sensors: position, pressure, and 
force.  The position sensor (DC Fastar DCFS3/4-M LVDT [29]) was mounted at the top of the 
device and measured the position of the piston assembly.  The piezoelectric pressure sensor 
(Kistler type 211B1 [12]) was mounted in the drug cylinder and measured the pressure of the 
fluid in the cylinder.  The force sensor (Futek 250-lb load cell [8]) was included in the design to 
measure the force needed for injection.  This data would be used to determine the specifications 
of the actuator for future devices.   
5.1.5 Electronics and Software 
The electronics for the system and the control software were the Master of Engineering thesis 
project of Brian Hemond.  (For a more in-depth discussion of the electrical side of this project, 
please see his thesis [10]).  The voice coil was powered by a linear amplifier (AE Techron [2] 
LVC 5050) under the control of the system’s programmed control logic (PCL) written by Brian 
Hemond.  The PCL sent a voltage signal (“waveform”) to the amplifier that then amplified it and 
sent it to the voice coil.  The PCL also recorded the sensor outputs.  The user interface (Figure 
10) filtered and displayed the sensor signals, as well as the voltage and current sent to the coil 
during the injection.   
 
 
 
Figure 10: The user interface of the programmed control logic.  Each of the black panels displays 
plots of the sensor feedbacks during an injection.  The software also automatically logged all data 
(raw and filtered) to a comma-separated-variable file.   
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Varying the voltage signal sent by the PCL changed the parameters of the injection.  Increasing 
the voltage led to higher pressure in the fluid due to the increased force generated by the voice 
coil and transmitted to the fluid through the piston assembly.  Therefore increasing the voltage 
resulted in higher jet power at the nozzle.  Each voltage waveform corresponded to a jet power 
waveform whose results in tissue were then observed.   
5.2 Device Characterization 
The benchtop device was tested to verify that it was capable of injection.   
5.2.1 Repeatability 
The repeatability of the injected volume was tested before performing any biological injections.  
Ten injections were made using the same control parameters.  The fluid ejected from the nozzle 
was collected in Eppendorf tubes and measured.  The results are shown in Figure 11. 
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Figure 11: Volume of fluid ejected from benchtop NFI device in 10 sequential trials.   
 
There was considerable variability between injections (standard deviation: 5.9 µL).  This would 
be problematic in biological injections because the amount of drug injected would vary widely.  
The repeatability would need to be improved in the next design iteration.  
5.2.2 Polyacrylamide Dye Injections 
We confirmed the device was capable of injections into polyacrylamide gels and achieved results 
similar to Schramm-Baxter’s results [25] (Figure 12).  
 
 
 
 
2 ms 3 ms 4 ms 5 ms1 ms 
Figure 12: Sequential photographs of needle-free injection of 0.1% Bromocresol Green dye solution into  
polyacrylamide gel using high speed videography (Phantom V9 camera by Vision Research [31]).   
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5.2.3 In Vitro Dye Injections 
After the polyacrylamide gel testing proved that the device was able to successfully inject fluid, 
testing in tissue samples was performed.  Injections into postmortem skin from a 6-month old 
lamb showed that the device could inject into tissue (Figure 13).  A 0.1% solution of the dye  
Bromocresol Green was injected into the tissue.    
 
 
Figure 13: Tissue sample cut in half and laid open to view the injection depth from the benchtop 
proof-of-concept device.  This injection went into the dermis of the tissue, with the majority of the 
fluid between 1 and 4 mm deep.   
 
Also, in vitro testing showed that by varying the voltage waveform (and therefore the jet power 
waveform), different depths of injections were possible (Figure 14).   
 
 
 
Figure 14: Tissue samples cut in half and laid open to view the injection depth from the benchtop 
proof-of-concept device.  Each of the samples was injected using a different voltage waveform 
(and therefore a different jet power).  The sample on the left was injected using a low jet power, 
the sample on the right using high jet power, and the sample in the middle using an intermediate 
jet power.  The wool that was on each sample when it was injected has been trimmed off and 
placed above the sample.    
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5.2.4 In Vitro Activity Testing 
After the success of the dye injections, it was necessary to see if the NFI system could inject an 
enzyme and whether that enzyme would continue to be active in the tissue.  Therefore, biological 
activity tests were performed with the enzyme collagenase.  Collagenase was chosen because 
assays for its activity are well-documented and its well-known pathology would make it useful 
for later in-vivo trials. 
 
The experiments were performed using a biological buffer solution (1xRB) as the control and a 
collagenase mixture named C7926.  Injections were performed into tubes and into in-vitro tissue 
samples.  The volume of fluid was determined by measuring the mass of the samples before and 
after injection.  The volume of fluid ejected for each sample is shown in Figure 15. 
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Figure 15: Volume of fluid ejected during experiments to test the activity of the enzyme 
collagenase after being used in the NFI Benchtop Proof of Concept.   
 
Activity assays designed, performed, and analyzed by Dr. Cathy Hogan showed that the 
collagenase was still active after being ejected from the nozzle into a tube and that it was still 
active after being injected into tissue.   
5.2.5 Summary of Results 
The benchtop proof-of-concept device proved that needle-free injection can be performed using a 
device actuated by a voice coil.  It also showed that a voice-coil-actuated NFI system could be 
controlled to inject to different depths.  The NFI device was able to inject an enzyme into sheep 
tissue without causing it to denature.  These results were promising enough for the project to 
move on to the design and manufacture of a handheld prototype device.   
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6 Handheld Prototype 
 
We created a conceptual design of a handheld NFI device, shown in Figure 16. 
 
 
 
Figure 16: Conceptual design of a handheld controllable needle-free injector.  The overall 
architecture is based on a hammer-drill design, with the possibility of a removable battery on the 
bottom of the handle. 
 
A model of the device was created using stereolithography (SLA) as shown in Figure 17. 
 
 
 
Figure 17: Rapid-prototype of conceptual design of a handheld controllable needle-free injector.   
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However, before moving on to such a streamlined, commercial design, the handheld prototype 
was designed and created with ease of manufacture and replaceable components for testing. 
6.1 Device Design 
The device design was changed from a vertical configuration in the benchtop device to a 
horizontal configuration for the handheld device.  The axial alignment of the elements 
was achieved by an aluminum housing designed by Dr. Bryan Crane.  Handles were 
added and several improvements over the benchtop proof-of-concept device were 
implemented.  A cutaway CAD view and the finished device are shown in Figure 18.   
 
 a. 
 
 
b. 
 
Figure 18: (a) Cutaway CAD model of the handheld NFI prototype and (b) the device (upside 
down so the pressure sensor and refill ports are visible).   
 
6.1.1 Drug Cylinder 
The drug cylinder design was similar to that of the benchtop device but the location of some of 
the fluid passageways was changed to make it easier to purge the air from the system when first 
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filling the device with liquid (Figure 19).  Also, the cylinder was made out of stainless steel for 
increased corrosion resistance and biological compatibility.   
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Figure 19: Cutaway CAD view of the drug cylinder and nozzle.  Note the changed locations of the 
pressure sensor bore and bleed port channel.  Also note the o-ring groove at the front of the 
cylinder. 
 
Another design change from the proof-of-concept was the inclusion of an o-ring groove on the 
face of the cylinder (Figure 20).  This o-ring prevented fluid leakage at the interface between the 
drug cylinder and the nozzle. 
 
 
 
Figure 20: The face of the drug cylinder.  Note the o-ring groove.  The circle of holes outside of 
the groove are mounting holes for the nozzle.   
   
6.1.2 Nozzle 
The nozzle was redesigned for use with sheep, where wool on the samples (and on live animals) 
would be in the way.  Labmate Nicaulas Sabourin designed the nozzle with a narrow, tapered tip 
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to allow the nozzle to penetrate matted wool and contact the sheep’s skin (Figure 21a).  He 
machined it using a CNC lathe [32].  A nozzle cap was designed with a bi-stable, spring-
tensioned system that would seal off the nozzle so that drug was not wasted and air could not 
enter the system while automatically reloading (Figure 21b).   
 
a.      b.   
 
Figure 21: (a) The redesigned nozzle with mounting holes and a 100 µm hole. (b) The nozzle cap 
in place and closed over the nozzle. 
 
Three different sizes of nozzle were prepared: 200 µm, 100 µm, and 50 µm.  The 50 µm nozzle 
was easily clogged by particulates in the system and ultimately only the 200 µm and 100 µm 
nozzles were used for testing.   
6.1.3 Voice Coil and Piston Assembly 
The same voice coil was used in the handheld device (BEI Kimco model LA25-42-000A).   The 
piston assembly was also similar to the benchtop proof-of-concept, except that the force sensor 
was removed from the system and replaced with an axial misalignment coupling to prevent the 
system from being overconstrained.  Also, instead of using a 3 mm shaft as the piston, a piston 
from a Hamilton [7] syringe (model 5495-30, 1750.5TLLX 250 uL Syringe W/STP) was used to 
improve the seal inside the drug cylinder (Figure 22).   
 
 
 
Figure 22: The misalignment coupling with the Hamilton syringe piston. 
6.1.4 Auto-loading System 
Automatically loading the device with fluid would reduce errors and increase its throughput.  
Therefore, an auto-loading system was designed by Brian Hemond.  By attaching a 50 mL test 
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tube with screw-on cap to the refill port and selectively pressurizing the test tube with argon, the 
device could be refilled automatically by the software after each injection. 
6.1.5 Sensors 
The position and pressure sensors were the same ones used in the benchtop proof-of-concept.  
The force sensor was not included in the handheld prototype.   
6.1.6 Electronics and Software 
The electronics and software were similar to the benchtop proof-of-concept, with only minor 
revisions and updates to the software as needed to improve functionality or add safety checks so 
the device could not be fired until it had been filled with fluid.   
6.2 Device Characterization 
The handheld prototype was tested after its completion to make sure that it performed as 
expected.   
6.2.1 Repeatability 
Repeatability of the device was tested with the 100 µm and 200 µm nozzles.  The results (Figure 
23) show that the device fires repeatably with either nozzle.  The red “error” bar of the graph 
indicates the difference between the amount of fluid measured that exited the nozzle and the 
theoretical amount of fluid that should have exited based on the travel of the piston (measured by 
the position sensor).  Differences in the theoretical and actual volumes could be caused by air in 
the system, small losses of fluid out the bleed port or through the check valve, errors in the 
position sensor measurement, a drop of fluid left on the device nozzle, or other factors. 
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Figure 23: Repeatability of volume of fluid ejected from the handheld prototype device.  The 
green bars correspond to the 100 µm nozzle and the blue bars correspond to the 200 µm nozzle.  
The red bars indicate the difference between the theoretical volume ejected based on the position 
sensor and the measured volume ejected. 
 
24 
This device shows much better repeatability than the proof-of-concept device (standard deviation 
6.2.2 In Vitro Dye Injections 
e solution using the handheld prototype gave similar results 
is 3.3 µL for the 100 µm nozzle and 1.5 µL for the 200 µm nozzle).  Therefore, the amount of 
fluid injected into samples would be much more consistent, yielding better scientific results.   
Injections of Bromocresol Green dy
to those from the benchtop device experiments.  By varying the jet power profile, the depth of 
injection below the epidermis could be varied.  Also, it appeared that the most important 
parameter in determining the depth of injection was the peak jet power, as shown in Figure 24.  
By increasing the peak jet power, the depth of the injection increased dramatically. 
 
 
2 mm
2 mm
 
Figure 24: Depth of injection increases as peak jet power increases. 
 
he controllability of the device provided an opportunity to develop voltage waveforms precisely T
for each depth of injection need.  Also, the waveforms would need to be different for each nozzle 
diameter if it was indeed the jet power that indicates the depth of the injection (as theorized in 
Section 4.2).  Therefore, many different voltage waveforms were created and tested on tissue all 
using the same handheld device.  We focused on waveforms that delivered liquid to the dermis, 
since this is the optimal location for collagenase delivery.  A summary of results for the 100 µm 
and 200 µm nozzle waveforms is shown in Figure 25.  Several quantitative parameters were 
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calculated by an imaging program written by Andrea Bruno in Matlab [21] (see Appendix C) and 
the averages are presented in the figure as well.  Some waveforms appear to produce more 
uniform injections, which is desirable.  Also, the average depth of injection is important, which 
is quantified by the two Mean Depth measurements.  
 
100um nozzle waveforms
WF = 520      - 4 injections; 
mean Depth_Com = 4.59 [mm]; mean Depth_hP = 9.33 [mm] 
mean Orientation = 96.78 °
WF = 568      – 5 injections; 
mean Depth_Com = 2.08 [mm]; mean Depth_hP = 4.09 [mm]
mean Orientation = 88.52 °
WF = 555 - 5 injections; 
mean Depth_Com = 4.10 [mm]; mean Depth_hP = 6.28 [mm] 
mean Orientation = 74.65 °
WF = 567 - 5 injections; 
mean Depth_Com = 2.44 [mm]; mean Depth_hP = 3.93 [mm] 
mean Orientation = 94.51 °
WF = 566 - 5 injections; 
mean Depth_Com = 2.52 [mm]; mean Depth_hP = 4.24 [mm] 
mean Orientation = 95.47 °
WF = 564 - 4 injections; 
mean Depth_Com = 3.11 [mm]; mean Depth_hP = 5.86 [mm] 
mean Orientation = 98.91 °
200um nozzle waveforms
WF = 570      - 4 injections; 
mean Depth_Com = 2.96 [mm]; mean Depth_hP = 4.52 [mm] 
mean Orientation = 85.25 °
WF = 571      – 4 injections; 
mean Depth_Com = 2.13 [mm]; mean Depth_hP = 3.74 [mm]
mean Orientation = 92.87 °
WF = 572 - 4 injections; 
mean Depth_Com = 2.81 [mm]; mean Depth_hP = 4.48 [mm] 
mean Orientation = 90.00 °
WF = 573 - 4 injections; 
mean Depth_Com = 2.99 [mm]; mean Depth_hP = 4.42 [mm] 
mean Orientation = 96.33 °
WF = 574 - 4 injections; 
mean Depth_Com = 3.11 [mm]; mean Depth_hP = 4.39 [mm] 
mean Orientation = 98.15 °
 
Figure 25: Injection results for different waveforms created for the 100 µm and 200 µm nozzles 
with the goal of injecting fluid into the dermis.  The selected waveforms used for in-vivo 
experimentation are circled in green.  (Figure courtesy of Andrea Bruno). 
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6.2.3 I
In vitro a
performed with the benchtop device.  The results were the same: the collagenase is still active 
after being injected into a test tube or into tissue from the handheld controllable NFI prototype.   
6.2.4 In Vivo Activity Testing 
After repeatability testing, in-vitro injection depth testing, and in-vitro activity testing, the next 
step was to test the handheld device on a live sheep.  A 10 week old Suffolk-cross wether was 
chosen as the test subject.  The collagenase mixture from the activity testing was injected into the 
midside of the animal and the response was monitored for several weeks.  Controls consisted of 
1xRB buffer injected via the NFI, 1xRB buffer injected by a conventional 27.5 gauge needle 
(190.5 µm diameter), and collagenase injection by a 27.5 gauge needle.  The outline of the test 
locations is shown in Figure 26.   
 
n Vitro Activity Testing 
ctivity testing with collagenase was performed the same way as the activity assays were 
10 mm
Dorsal
Ventral
Anterior Posterior
NFI control
(1x RB)
27.5G needle
Negative Control
NFI test sample
(Collagenase)
27.5G needle 
Positive Control
 
Figure 26: Location of test injections on the midside of a 10-week old Suffolk-cross wether. 
 
The lamb was sedated while the injections were performed.  The injections with the prototype 
device were performed by Dawn Wendell and the needle injections were performed by Dr. Cathy 
Hogan (Figure 27).  The intended depth of the injection was into the dermis, about 2 to 4mm 
deep in the tissue.     
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Figure 27: (a) Dawn Wendell uses the handheld NFI prototype. (b) Dr. Cathy Hogan injects with 
conventional 27.5 gauge syringe. (c) Closeup of  the nozzle of the NFI prototype; the nozzle is 
penetrating the wool layer.  
 
During the injections, a small amount of blood appeared at two of the NFI injection sites.  
Otherwise, there was no noticeable difference between the needle injections and the NFI 
injectio
shaved so that Dr. Hogan could acquire biopsies to check for cellular 
vidence of collagenase activity.  Visually, it was clear from the results of the experiment that 
the 1xRB buffer had no effect whether it was injected by the NFI or by a needle, and that 
collagenase caused similar hair loss and scarring whether it was injected by the NFI or a needle 
(Figure 28).   
 
 
ns.  The lamb was monitored for more than 6 weeks after the injections.   
6.2.5 Summary of Results 
Over the course of 6 weeks of monitoring the lamb, photographs were taken of each of the 
injection sites.  A summary of the results is shown in Figure 28.  At Day 9 post-injection, the 
injection sites were 
e
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NFI Control
Negative Control
Day 9 Day 21Day 0 Day 28 Day 35 Day 43
Positive Control
NFI Test
 
Figure 28: Results of injections of 1xRB buffer and collagenase into lamb midside using NFI and 
conventional needle injections.  In the figure, NFI Control refers to injections of buffer via the 
NFI, NFI Test refers to injections of collagenase via the NFI, Positive Control refers to needle 
injections of the collagenase, and Negative Control refers to needle injections of the buffer.  
(Figure courtesy of Dr. Hogan). 
 
The biopsy plugs that were taken on Day 9 were trimmed and prepared for paraffin embedding 
by Dr. Hogan.  The samples were then sent to the MIT Histology Lab where they were 
embedded, sectioned, and stained with Masson’s Trichrome (which stains collagen blue).  
Photom ples can be seen in Figure 29. 
 
icrographs of the sam
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Figure 29: Photomicrographs of tissue sections stained with Masson’s Trichrome, 9 days post-
injection.  Both samples injected with buffer look similar to each other and similar to healthy 
tissue.  Both samples injected with collagenase look similar to each other and significantly 
different than normal tissue.  The collagenase- d tissue samples show changes in tissue 
morphology including a thickened epidermis, distruption of hair follicles, and proliferation of 
collagen.  (Images courtesy of Dr. Hogan). 
injecte
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The samples injected with buffer both appear normal, but the samples injected with collagenase 
show changes in tissue morphology: thickened epidermis, disrupted hair follicles, and a 
proliferation of collagen.  The proliferation of collagen is a typical wound response to injection 
with collagenase.   
 
These in-vivo experiments prove that collagenase is still active after injection with the handheld 
NFI device, and that NFI injection of collagenase is comparable to needle injection in sheep 
midside. 
 
7 Conclusions and Future Directions 
 
A handheld controllable needle-free injection device was designed and manufactured using a 
oice coil as the cov ntrollable actuator.  The device was capable of injections of different depths 
collagenase delivered by a 27.5 gauge needle.   
The future work that would most benefit the controllable NFI project would be to create a tissue 
model that would allow the correlation of jet power with depth of injection.  This model would 
probably vary based on the animal species, age, and perhaps even breed.  However, this 
understanding would allow the user of a controllable NFI in the field to “dial in” the depth of the 
injection necessary and then have the controllable actuator deliver an injection with the 
appropriate jet power to produce that depth.  This also has implications for a human market for 
this device.  By adjusting the depth of injection, it could be possible to minimize pain and deliver 
drug to the correct depth every time, unlike a needle where medical errors can result in incorrect 
injections.  Future work in this area could drastically improve healthcare for animals and humans 
alike.   
 
into tissue based on the driving voltage waveform given to the voice coil.  Collagenase injected 
by the device was still active post-injection in sheep tissue in-vitro and in-vivo.  Also, 
collagenase delivered by the controllable NFI device resulted in the same pharmacological 
esults as r
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Appendix A: Selected Device Drawings 
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Appendix B: Matlab Script for Jet Power Calculation 
clear; 
  
%******************************************* 
% 
% NW Abbey Needless Injection Analysis 
%              March 15 2005 
%          Single File Analysis 
%   (edited for new software channels) 
%  modified to calculate volume ejected based on initial and final piston 
%   position 8-15-05 
%  added jet power and jet velocity to the graphs  9-19-05 
%******************************************** 
  
  
%Change directory to where data is 
%cd 'C:\Documents and Settings\Dawn M. Wendell\Desktop\injector 
software\bin\Debug'; 
  
%Choose file to be analyzed 
first = input('Enter the first file number you wish to analyze: ','s'); 
last = input('Enter the last file number you wish to analyze: ','s'); 
noz = input('Nozzle? (enter 1 for 100um, 2 for 200um): '); 
  
colors = ['r  '; 'g  '; 'b  '; 'm  '; 'k  '; 'y  '; 'c  '; 'r--'; 'g--'; 'b--
'; 'm--'; 'k--'; 'y--'; 'c--'; 'r-.'; 'g-.'; 'b-.'; 'm-.'; 'k-.'; 'y-.'; 'c-
.'; 'r  '; 'g  '; 'b  '; 'm  '; 'k  '; 'y  '; 'c  '; 'r--'; 'g--'; 'b--'; 'm-
-'; 'k--'; 'y--'; 'c--'; 'r-.'; 'g-.'; 'b-.'; 'm-.'; 'k-.'; 'y-.'; 'c-.']; 
  
datanums = str2num(first):str2num(last); 
  
for j=str2num(first):str2num(last); 
file = strcat('data',num2str(j),'.csv'); 
color = colors(j-str2num(first)+1,:); 
  
%Load Files 
    data = csvread(file,8,1); 
  
%Split Data 
    pressure = data(:,9)*11; 
    position = (data(:,8))*2; % - data(1,10)); 
    position = position-min(position); 
   % voltage = data(:,10)*2; 
   % current = data(:,11); 
   % drive = data(:,12)*10; 
    time = data(:,1); 
    t = time; 
    %velocity = (position(2:length(position))-position(1:length(position)-
1))/(time(2)-time(1)); 
    %velocity = velocity*5;  %fixes units 
     
    pos1 = position/2; 
    A_bore = 3.1415/4*(0.1285*25.4)^2;  %mm^2 
    V_swept = A_bore*(pos1(end)-pos1(1)); 
 
35 
    A_noz = 3.1415/4*((noz*0.1)^2);  %mm^2 
Integrated Bernoulli 
me = 0; 
 = sqrt(2000*pressure); 
nits (m, sec) 
ot Data 
ure,color); 
,1) 
L)') 
atts)') 
    %velocity = velocity*(A_bore/A_noz)/100; 
     
%
    volu
 vel   
    for i=1:length(pressure); 
 volume = volume + (0.1*A_noz*vel(i));    
    vol(i) = volume; 
    end; 
    volume; 
  
%Jet Power 
r     rho=1000;    %wate
    Po=0.5*rho*(A_noz/1000000)*vel.^3;    %all in standard u
    maxPo = max(Po); 
     
%Pl
    figure(1); 
     
    subplot(5,1,1) 
 HP = plot(t,press   
    xlim([0 100]) 
    ylim([0 75]) 
    set(HP, 'LineWidth',1) 
    ylabel('Pressure (MPa)') 
 hold on    
    grid on 
     
    subplot(5,1,4) 
    HC = plot(t,vel,color); 
  set(HC, 'LineWidth',1)   
    ylabel('Jet Velocity (m/s)') 
 hold on    
    grid on 
     
    subplot(5,1,2) 
  HD = plot(t,position,color);   
    set(HD, 'LineWidth'
    ylabel('Position (mm)') 
  hold on   
    grid on 
     
    subplot(5,1,3) 
    HD = (plot(t,vol,color)); 
    set(HD, 'LineWidth',1) 
u    ylabel('volume ejected (
    hold on 
    grid on 
    
    subplot(5,1,5) 
    HD = (plot(t,Po,color)); 
    set(HD, 'LineWidth',1)   
abel('time (msec)')     xl
    ylabel('Jet Power (W
    hold on 
    grid on 
36 
     
    subplot(5,1,1) 
    title('Injection Results') 
(datanums); 
, 'LineWidth',1) 
ressure (MPa)') 
 xlabel('Time (ms)') 
e(datanums); 
num2str(datnums)) 
,strcat('Swept Volume = ',num2str(V_swept))) 
lotyy(t, voltage, t, position); 
Width', 2); 
),'Ylabel'),'String','Position (mm)') 
70]) 
) 
1),'YTick', 0:10: max(voltage)) 
2),'YLim', [0 2*mean(position)]) 
(2),'YTick', 0:1: 2*mean(position)) 
0]); 
, 'current in amps', 'drive x 10', 'voltage in 
 'velocity m/s /10', 'calc vol ejected/2 
rcat('Results for  ',x))      
    datnums = transpose
    legend(num2str(datnums)) 
     
    figure(2); 
    HP = plot(t,pressure,color); 
    ylim([0 70]) 
    set(HP
    ylabel('P
   
    hold on 
    grid on 
    title('Injection Pressures') 
    datnums = transpos
    legend(
end 
  
    %text(32.5,27.5
%     [AX,H1,H2] = p
%     set(H1, 'LineWidth', 2); 
%     set(H2, 'Line
%     set(get(AX(2
%     set(AX(1),'YLim', [0 1
%     set(AX(1), 'XLim',[0 60]
%     set(AX(
%     set(AX(
set(AX%     
   % axis([0 100 0 7
   % legend('pressure in MPa'
volts', 'position in mm x2',
(uL)','Jet power (Watts)') 
  
   % title(st
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Appendix C: Matlab Script for Quantitative Tissue 
no, printed with permission) 
 
 limited: 
ge to avoid tracking dye that is not in 
imative lines of separation between epidermis 
 and subcutaneus fat. Then she needs to 
interest) to further keep the algorithm to 
yed hair or scene background) 
gs\andrea\My 
ents\Work\injectionCampaign_june3'; 
se all 
%% image load 
athname = 'C:\Documents and Settings\andrea\My 
ocuments\Work\injectionCampaign_june3'; 
d(pathname); 
filename, pathname] = uigetfile(  { '*.jpg',  'Jpeg file (*.jpg)'; ... 
   '*.bmp','Bitmap file(*.bmp)'; ... 
   '*.tif','Tif file (*.tif)';}, ... 
   'Pick an image'); 
insertmass(filename); 
I = imread([pathname,filename]); 
imshow(I) 
  
  
%% crop image step 
% It allows to limit the size of the processed image in order to speed up 
% the algorithm 
Ic = imcrop(I); 
imshow(Ic) 
Ic = im2double(Ic); 
  
Comparison (by Andrea Bru
 
%% Introduction;
%The user's intervention is really
to crop the ima%Mainly she needs 
%the tissue, draw the approx
%and dermis and between dermis
 of %choose the ROIs (regions
ng zones (d%apply to wro
  
% set directory default; 
clear; 
ettinpathname = 'C:\Documents and S
Docum
clo
try  
    load data.mat  
    catch 
end 
  
index =[]; 
try 
    index = data(end).Index; 
 
catch 
 end
  
if isempty(index); 
    index = 1; 
se el
    index = index + 1; 
end 
     
 
p
D
c
[
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%% image processing step 
mooth the 
e 
ine; 
; 
=size(R); 
madjust(y1,stretchlim(y1),[0 1]); 
etchlim(y2),[0 1]); 
'holes'); 
ity rapresentation of the tracked dye'); 
mshow(y2),title('B-G'); 
, hold on, 
chosen in order to track the diffusion of the dye into 
 
mfilter(y2,filt),5); axis ij; 
,'TextStep',get(h,'LevelStep')*2) 
% The algorithm works in an RGB workspace. After filtering, to s
% image and ease the thresholding, the Blue dye is tracked subtructing th
% Red and Green channels to the Blu one. The algorithm uses also  
 morphological reconstruction to fill eventual holes. %
  
  filt = fspecial('disk',6);       
  If = imadjust(Ic,stretchlim(Ic),[0 1]); 
  If = imfilter(If,filt); 
   
 imshow(If), title('Draw approximative epidermis line') 
 xy_epidermis_est = gpointspline; 
tle('Draw approximative fat tissue line')  ti
 xy_tissue_est = gpointspl
  
 %  xy_2 = gpointspline; 
%  xy_3 = gpointspline; 
pointspline; %  xy_4 = g
    
R=Ic(:,:,1); 
; G=Ic(:,:,2)
:,:,3)B=Ic(
n][m,
  
 - R; y1 = B
y2 = B - G;  
  
 i%y1 =
   
y2 = imadjust( ,stry2
y2 = imfill(y2, 
  
imshow(y2),title('Intens
  
%%subplot(211),i
%subplot(212),imshow(y1),title('B-R'); 
   
n. %% BW conversio
% A black and white conversion is accomplished to easily extract 
haracterized the injection. % morphological parameters useful to c
   
 % g = round(ginput(1))
% v = y2(g(2),g(1))  
  
ecial('disk',7); %filt = fsp
show(If)%im
  
%Two thresholds are 
%the tissue. This is done looking at the intensity values of the subtracted
gher is the intensity, the more concentrated is the dye. %channels. The Hi
  
our(i[C,h] = cont
set(h,'ShowText','on'
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BW = im2bw(y2,0.33); 
imshow(BW), title('select ROI - Low Intensity') 
BBB = roipoly;
BWL = BBB.*BW; 
 
   
BW = im2bw(y2,0.83);
imshow(BW), title('ROI - High Intensity') 
 
BBBL = roipoly; 
BWH = BBBL.*BW; 
Low Intensity'); 
tensity'); 
res a set of properties for 
ese, like the Area, are calculated working directly 
images. ther, as center of mass, are calculated using the Intensity 
double(BWH),'Area', 
ntation','Solidity','Extrema'); 
itle('Injected stuff') 
oid','Extrema','Orientation'); 
extreme point 
; 
; 
  %%% Left extreme point 
ermis_est,lPsx,lPdx); 
 =      0.0147; %fastcal; 
  
subplot(211), imshow(BWL),title('select ROI - 
subplot(212), imshow(BWH),title('ROI - High In
  
%% Regions analysis  
% The algorithm then me uas
% each ROI. Someone of th
on the 
% BW  O
% image. 
  
h = regionprops(
'Centroid','Orie
  
%imshow(y2), t
  
l = regionprops(double(BWL),'Area', 'Centr
  
centroids = centroid(y2.*BBB); 
BBL); centroidsl = centroid(y2.*B
  
 el_sx = l.Extrema(7:8,:); 
el_dx = l.Extrema(3:4,:); 
  
[lsx,pos] = min(el_sx(:,1)); 
lPsx = [lsx,el_sx(pos,2)];     %%% Left 
  
[ldx,pos] = max(el_dx(:,1)); 
 lPdx = [ldx,el_dx(pos,2)];     %%% Right extreme point    
  
eh_sx = h.Extrema(7:8,:)
:)eh_dx = h.Extrema(3:4,
  
[hsx,pos] = min(eh_sx(:,1)); 
hPsx = [hsx,eh_sx(pos )];   ,2
  
[hdx,pos] = max(eh_dx(:,1)); 
hPdx = [hdx,eh_dx(pos,2)];     %%% Right extreme point     
  
sition_HighDens,side] = grelpos(xy_tissue_est, [po
xy_epidermis_est,hPsx,hPdx); 
[position_LowDens,side] = grelpos(xy_tissue_est, xy_epid
  
res
40 
  
%% Visual proof 
% Of course, image are saved to allow the operato
it
r to check and determine 
of the injection using her qual ative assessment as well 
ative parameters.  
re1 = figu ('Color',[1 1 1]); 
,... 
YDir','reverse',... 
bel('[mm]'); 
t(hPsx(1)*res,hPsx(2)*res,'+','Color',[0,1,0]) 
r',[0,1,0]) 
epidermis_est(2,:)*res,'b--');  
epidermis_est(2,1)*res,'\leftarrow E-D 
,'Color','b') 
,xy_tissue_est(2,:)*res,'r--'); 
t(xy_tissue_est(1,end)*re xy_tissue_est(2,end)*res,'\leftarrow D-F 
lot(centroids(:,1), centroids(:,2), 'b*')
idsl(:,2), '+') 
p = DYLP; 
- 2. point hp'); 
 hP = ginput(1)/res;
*res,xy_epidermis_est(2,:)*res,'b--'); 
% the qualitity 
% as the quantit
refigu
  
axes1 = axes(... 
..   'Layer','top',.
  'TickDir','out'
  '
  'Parent',figure1); 
[m,n] = size(Ic(:,:,1)); 
 [1:n]*res; x =
y = [1:m]*res; 
  
imshow(Ic,'XData',x,'YData',y) 
axis on, grid on,  
hold on 
  
yla
   
if side == 1   %epidermis at the right side 
plo
plot(lPsx(1)*res,lPsx(2)*res,'o','Colo
e  els
plot(hPdx(1)*res,hPdx(2)*res,'+','Color',[0,1,0]) 
t(lPdx(1)*res,lPdx(2)*res,'o','Color',[0,1,0]) plo
end 
plot(xy_epidermis_est(1,:)*res,xy_
t(xy_epidermis_est(1,1)*res,xy_tex
ABL',... 
     'HorizontalAlignment 'left'',
plot(xy_tissue_est(1,:)*res
tex s,
ABL',... 
     'HorizontalAlignment','left','Color','R') 
 % p
% plot(centroidsl(:,1), centro
  
res
  
if resp == 'No!' 
  
    title('Pick: 1. point lP  
    lP = ginput(1)/res; 
    
    close; 
    imshow(Ic,'XData',x,'YData',y) 
 axis on, grid on,    
    hold on 
    plot(hP(1)*res,hP(2)*res,'+','Color',[0,1,0]) 
    plot(lP(1)*res,lP(2)*res,'o','Color',[0,1,0]) 
  
    plot(xy_epidermis_est(1,:)
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    text(xy_epidermis_est(1,1)*res,xy_epidermis_est(2,1)*res,'\leftarrow E-D 
,'Color','R') 
distance(If,lP,xy_epidermis_est); 
stance(If,hP,xy_epidermis_est); 
= distance(If,lP,xy_tissue_est); 
= distance(If,hP,xy_tissue_est);,'Color',[0,1,0] 
 
     [val_l  pos1] = distance(If,lPsx,xy_epidermis_est); 
e(If,hPsx,xy_epidermis_est); 
stance(If,lPsx,xy_tissue_est); 
r_pos2] = distance(If,hPsx,xy_tissue_est); 
pos1] = distance(If,lPdx,xy_epidermis_est); 
pos2] = distance(If,hPdx,xy_epidermis_est); 
dx,xy_tissue_est); 
tissue_est); 
); 
 ',' '''' 'jpeg' '''' 
e parameters are saved into a database. This structure has 
nformation: 
e processed image 
epidermis line and the 
Intensity Zone 
between the x-axis and the major axis 
econd-moments as the region 
ixels in the convex hull that are also 
ed as Area/ConvexArea (ConvexArea is the area in the 
io Area High intesity on 
enter 
ABL',... 
        'HorizontalAlignment','left','Color','b') 
    plot(xy_tissue_est(1,:)*res,xy_tissue_est(2,:)*res,'r--'); 
_tissue_est(2,end)*res,'\leftarrow D-F     text(xy_tissue_est(1,end)*res,xy
ABL',... 
     'HorizontalAlignment','left'   
   
    [val_lP, pos1] = 
    [val_hP, pos2] = di
    [tiss_lP, der_pos1] 
]     [tiss_hP, der_pos2
   
else 
    if side == 1
P,   
        [val_hP, pos2] = distanc
r_pos1] = di        [tiss_lP, de
tiss_hP, de        [
 else    
        [val_lP, 
    [val_hP,     
        [tiss_lP, tiss_pos1] = distance(If,lP
        [tiss_hP, tiss_pos2] = distance(If,hPdx,xy_
    end 
end 
  
[val, pos] = distance(If,centroids,xy_epidermis_est
  
imname = filename(1:end-4); 
for gg = 1:length(imname) 
    if imname(gg) == '-' 
        imname(gg) = '_'; 
    end 
end 
  
cd([pathname '\pics']); 
eval(['saveas(gcf' ',' '''' imname 'ELAB.jpg' ''''
')']);  
  
%% SAVE DATA 
Quantitativ%  
%  the following i
ame: Name of th% N
% Depth_CoM: Distance between the approximative 
igh intensity ROI % center of mass of the h
% Area: Area of the High 
n: the angle % Orientatio
% of the ellipse that has the same s
tion of the p% Solidity:  the propor
on. Comput% in the regi
convex hull, 
% with all pixels within the hull filled in. 
iffusion: Three component: [a b c]; a is the rat% D
Area 
% Low intensity; b is magnitude of the differnce vectore between the c
42 
%of mass of the High intensity region and Low intensity region; 
%c is the  direction of the previous vector; 
% Depth_lP: greatest depth of the Low intensity zone (with res ct to the 
s) 
sity zone (with respect to 
sub fat tissue)
 zone (with respect 
ighDensity:  reminder of the position of High intensity zone 
fference between mass before injection and after the 
ea/l.Area; 
(2)); 
      imagesc(Ic); hold on,axis ij 
 
')' '= struct(' '''' 'Name' '''' ',' 'imname' 
  'val*res' ',' '''' 'Area' '''' ','... 
'' 'Orientation' '''' ... 
 '''Solidity''' ',' 'h.Solidity' ',' '''' 
n' '''' ',' '[Dif,magn,ang]' ',' ... 
'' 'Depth_lP_Derm' '''' ',' 'val_lP*res' ',' '''' 'Depth_hP_Derm' '''' 
 ',' ... 
s' '''' ',' 'tiss_lP*res' ',' '''' 
'PosHighDensity' '''' ',' 'position_HighDens'  ',' ... 
ctedMass' '''' ',' 'mass' ',' ... 
]); 
pe
epidermis) 
% Depth_hP: greatest depth of the High intensity zone (with respect to the 
% epidermi
% Depth_lP_subTiss: greatest depth of the Low inten
 the 
% Depth_hP_subTiss: greatest depth of the High intensity
to the 
% sub fat tissue) 
  
sLowDensity: reminder of the position of High intensity zone % Po
% PosH
% InjectedMass: Di
% injection (user's input) 
% WaveForm: user's input 
% Index: database index; 
  
Dif = h.Ar
vect = centroidsl(1)-centroids(1) + i*(centroids(2)-centroidsl
magn = abs(vect)*res; %[mm] 
ang = angle(vect); 
ang = angle(vect)*180/3.14; %[degree] 
    
%    
%          plot(centroids(1),centroids(2),'+'),
%          plot(centroidsl(1),centroidsl(2),'o') 
 
eval(['data(' num2str(index) 
,'',' '''' 'Depth_CoM' '''' '
    'h.Area*res*res' ',' ''
    ',' 'h.Orientation' ','
'Diffusio
'     '
 'val_hP*res'','
    '''' 'Depth_lP_SubTis
'Depth_hP_SubTiss' '''' ',' 'tiss_hP*res' ',' ... 
    '''' 'PosLowDensity' '''' ',' 'position_LowDens' ',' ... 
 ''''    
    '''' 'Inje
    '''' 'WaveForm' '''' ',' 'waveform' ',' '''' 'Index' '''' ',' 'index)'
  
%% Clear 
cd(pathname); 
data(end) 
if index == 1; 
save data.mat data %-append   
else  
 save data.mat data -append   
end 
close all 
clear all 
load data.mat 
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%% Edge finding 
% % create disk-shaped structure element 
% se = strel('rectangle', [20,20]); 
%  
% % perform bottom hat filter 
% Ibot = imbothat(P, se); 
%  
% % perform top hat filter 
% Itop = imtophat(P
%
, se); 
 subtract images to enhance contrast (lower right) 
e);
ys 
c, 2); 
Minor Axis Length (pixels)') 
rewit'); 
);  
 If = imadjust(If,stretchlim(If)); 
  
 rgb2hsv(If); 
sc(HSV) 
        
% %         P = hsv2rgb(P); 
  
% %
% Ienhance = imsubtract(imadd(Itop, P), Ibot); 
%  
% % convert objects of interest 
 % Iec = imcomplement(Ien ncha
%  
% % detect imtensity valle
emin = imextendedmin(Ie% I
% imshow(Iemin) 
% Iimpose = imimposemin(Iec, Iemin); 
% imshow(Iimpose) 
tation % % watershed segmen
% wat = watershed(Iimpose); 
how(wat) % ims
% % label separate regions 
% rgb = label2rgb(wat); 
% imshow(rgb)  
 % 
% % extract features from label matrix 
% stats = regionprops(wat, 'Area', 'Orientation'); 
% area = [stats(:).Area]; 
% orient = [stats(:).Orientation]; 
% figure('pos',[54 313 658 372]) 
% plot(area, orient, 'b*') 
% title('Relationship of Particle Orientation to Area') 
% xlabel('Area (pixels)'), ylabel('Orientation (deg)') 
% shg, pause 
%  
% % asses shape by exploring aspect ratio of detected features 
rAxisLength'); % stats = regionprops(wat,'MajorAxisLength','Mino
% figure, plot([stats.MajorAxisLength],[stats.MinorAxisLength],'.') 
label('Major Axis Length (pixels)') % x
% ylabel('
%  
%  
% BW = edge(P,'p
% imagesc(BW) 
%   
% % HSV workspace 
%       If = imfilter(Ic,filt  
% %        
% %        
%         HSV =
%         image
%  
44 
% %         subplot(2,2,1), imagesc(HSV(:,:,1)); title('H') 
ot(2,2,2), imagesc(HSV(:,:,2));title('S') 
:,3));title('V') 
   
 
m+1; 
e(y1,m*n,1); 
; 
% %         subpl
% %         subplot(2,2,3), imagesc(HSV(:,
); % %         subplot(2,2,4), imagesc(P
   %   
%         P = rgb2gray(P); 
lt);%         P = imfilter(P,fi
%   
% % YCBCR processing 
%  
CBCR = rgb2ycbcr(P); %  Y
%   
%   
 Fuzzy clustering % %%
% [n,m] = size(y1); 
% [N,M] = meshgrid(1:n,1:m); 
%  
% R=Ic(:,:,1); 
% G=Ic(:,:,2); 
% B=Ic(:,:,3); 
% [m,n]=size(R); 
% indice=m*n; 
% num=0; 
% for a1=1:m 
n %     for an=1:
%         data=R(a1,an); 
 %         data1=G(a1,an);
B(a1,an);%         data2=
      num=nu%   
%         VR(num)=data; 
%         VG(num)=data1; 
%         VB(num)=data2; 
%     end 
% end 
% VP=[VR;VG;VB]; 
% VPT=double(VP'); 
% [center,U,of]=fcm(VPT,7); 
%  
1 = reshap% ly
% ly2 = reshape(y1,m*n,1); 
% lN =  reshape(N,m*n,1); 
% lM =  reshape(M,m*n,1); 
%  
% fcmdata = cat(2,ly2,lN,lM); 
enter, U, obj_fcn] = fcm(fcmdata, 3)% [c
%  
%  
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